Anecdotal evidence abounds for CBD and hemp supplements, but what does the actual scientific literature say? What potential benefits are biologically plausible, why and how? What kind of doses are needed to elicit a health benefit? And what does the data really say about potential adverse events? In this webinar, our panel of experts will discuss the endocannabinoid system, and what peer-reviewed data does (and doesn’t) support for hemp-derived cannabinoids, including CBD, and terpenes.
Andrea Holmes, Ph.D.
Chief Growth Officer
Precision Plant Molecules
Douglas MacKay, N.D.
Senior Vice President of Scientific and Regulatory Affairs
Igor Koturbash, MD, PhD
Founder and Co-Director of the Center for Dietary Supplements Research
University of Arkansas for Medical Sciences
Stephen Daniells, PhD
Editor in Chief of the Americas
William Reed Business Media